Valvular heart disease in hyperprolactinemic patients treated with low doses of cabergoline.

Authors	Juan G Córdoba-Soriano, Cristina Lamas-Oliveira, Víctor M Hidalgo-Olivares, Antonia Tercero-Martínez, Moisés Barambio-Ruíz, Jesús Salas-Nieto
Journal	Revista espanola de cardiologia (English ed.) (Rev Esp Cardiol (Engl Ed)) Vol. 66 Issue 5 Pg. 410-2 (May 2013) ISSN: 1885-5857 [Electronic] Spain
PMID	24775830 (Publication Type: Letter)
Chemical References	Ergolines Cabergoline
Topics	Adult Cabergoline Ergolines (administration & dosage, adverse effects) Female Heart Valve Diseases (chemically induced) Humans Hyperprolactinemia (drug therapy) Male Middle Aged

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!